Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review

References

• American Cancer Society. About soft tissue sarcoma. Atlanta (GA): American Cancer Society; 2021.
   Google Scholar
• Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859–868. doi: 10.1200/JCO.1996.14.3.859.
   PubMed Web of Science ®Google Scholar
• Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefir of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203. doi: 10.1200/JCO.1998.16.1.197.
   PubMed Web of Science ®Google Scholar
• Lazarev S, McGee H, Moshier E, et al. Preoperative vs postoperative radiation therapy in localized soft tissue sarcoma: nationwide patterns of care and trends in utilization. Pract Radiat Oncol. 2017;7(6):e507–e516. doi: 10.1016/j.prro.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Salerno KE, Alektiar KM, Baldini EH, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11(5):339–351. doi: 10.1016/j.prro.2021.04.005.
   PubMed Web of Science ®Google Scholar
• Davis AM, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53. doi: 10.1016/j.radonc.2004.12.020.
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (eortc-62092: strass): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–1377. doi: 10.1016/S1470-2045(20)30446-0.
   PubMed Web of Science ®Google Scholar
• Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: eortc-62092 trial (strass) versus off-trial (strexit) results. Ann Surg. 2023;278(1):127–134. doi: 10.1097/SLA.0000000000005492.
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–1103. doi: 10.1016/s0959-8049(01)00083-1.
   PubMed Web of Science ®Google Scholar
• McCarter MD, Jaques DP, Brennan MF . Randomized clinical trials in soft tissue sarcoma. Surgical Oncology Clinics of North America. 2005;11(1):11–22.
   Google Scholar
• Miura JT, Charlson J, Gamblin TC, et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol. 2015;41(10):1386–1392. doi: 10.1016/j.ejso.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Bremjit PJ, Jones RL, Chai X, et al. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014;21(7):2150–2158. doi: 10.1245/s10434-014-3616-7.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype- tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (isg-sts 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–822. doi: 10.1016/S1470-2045(17)30334-0.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Miah AB, Dei Tos AP, et al.; ESMO Guidelines Committee, EURACAN and GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–1365. doi: 10.1016/j.annonc.2021.09.005.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio L, Touati N, Blay J-Y, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the european organization for research and treatment of cancer soft tissue and Cancer. 2020;126(11):2637–2647. doi: 10.1002/cncr.32795.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi: 10.1016/S1470-2045(14)70063-4.
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487–497. doi: 10.1016/s1470-2045(02)00818-5.
   PubMed Web of Science ®Google Scholar
• Issels RD, Abdel-Rahman S, Wendtner C-M, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (rht) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer. 2001;37(13):1599–1608. doi: 10.1016/S0959-8049(01)00183-6.
   PubMed Web of Science ®Google Scholar
• Wendtner C-M, Abdel-Rahman S, Baumert J, et al. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (sts) of adults: results of a phase ii pilot study (rht-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer. 2001;37(13):1609–1616. doi: 10.1016/s0959-8049(01)00191-5.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the eortc 62961-esho 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483–492. doi: 10.1001/jamaoncol.2017.4996.
   PubMed Web of Science ®Google Scholar
• V., Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. Leitlinienreport der S3-Leitlinie Adulte Weichgewebesarkome. AWMF Online. [Online] https://www.awmf.org.
   Google Scholar
• PRISMA. Prisma 2020 flow diagram. [Online] https://prisma-statement.org.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, s.l., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2017;18(11):e630. doi: 10.1016/S1470-2045(10)70071-1.
   PubMed Web of Science ®Google Scholar
• Leopold KA, DeWhirst M, Samulski T, et al. Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1992;22(5):989–998. doi: 10.1016/0360-3016(92)90798-m.
   PubMed Web of Science ®Google Scholar
• Prosnitz Leona R, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys. 1999;45(4):941–949. Vols. doi: 10.1016/s0360-3016(99)00272-2.
   PubMed Web of Science ®Google Scholar
• Maguire PD, Samulski TV, Prosnitz LR, et al. A phase ii trial testing the thermal dose parameter cem43° t 90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. Int J Hyperthermia. 2001;17(4):283–290. doi: 10.1080/02656730110039449.
   PubMed Web of Science ®Google Scholar
• DeWhirst MW, Poulson JM, Yu D, et al. Relation between po2, 31p magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(2):480–491. doi: 10.1016/j.ijrobp.2004.06.211.
   PubMed Web of Science ®Google Scholar
• De Jong MA, Oldenborg S, Bing Oei S, et al. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118(1):180–187. doi: 10.1002/cncr.26252.
   PubMed Web of Science ®Google Scholar
• Linthorst M, Van Geel AN, Baartman EA, et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother Oncol. 2013;109(2):188–193. doi: 10.1016/j.radonc.2013.05.010.
   PubMed Web of Science ®Google Scholar
• Eckert F, Gani C, Kluba T, et al. Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. Strahlenther Onkol. 2013;189(6):482–485. doi: 10.1007/s00066-013-0312-7.
   PubMed Web of Science ®Google Scholar
• Eckert F, Braun LH, Traub F, et al. Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas. Int J Hyperthermia. 2018;34(7):980–987. doi: 10.1080/02656736.2017.1369174.
   PubMed Web of Science ®Google Scholar
• Unsoeld M, Lamprecht U, Traub F, et al. Mr thermometry data correlate with pathological response for soft tissue sarcoma of the lower extremity in a single center analysis of prospectively registered patients. Cancers. 2020;12(4):959. doi: 10.3390/cancers12040959.
   PubMed Web of Science ®Google Scholar
• Spałek MJ, Borkowska AM, Telejko M, et al. The feasibility study of hypofractionated radiotherapy with regional hyperthermia in soft tissue sarcomas. Cancers (Basel). 2021;13(6):1332. doi: 10.3390/cancers13061332.
   Web of Science ®Google Scholar
• Rauch M, Agaimy A, Semrau S, et al. Long-term follow-up of patients receiving neoadjuvant treatment modalties for soft tissue sarcomas of the extremities. Cancers (Basel). 2021;13(20):5244. doi: 10.3390/cancers13205244.
   Web of Science ®Google Scholar
• Willner A, Fechner K, Agaimy A, et al. Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperi- toneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome. Strahlenther Onkol. 2021;197(12):1063–1071. doi: 10.1007/s00066-021-01830-0.
   PubMed Web of Science ®Google Scholar
• Issels RD, Prenninger SW, Nagele A, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase ii study. J Clin Oncol. 1990;8(11):1818–1829. doi: 10.1200/JCO.1990.8.11.1818.
   PubMed Web of Science ®Google Scholar
• J, Matuschek C, Bölke E, et al. Comparison of different systemic therapeutic regimes in resectable soft-tissue sarcoma—results of a network meta-analysis. Cancers. Cancers. 2021;13(22):5631. doi: 10.3390/cancers13225631.
   PubMed Web of Science ®Google Scholar
• RD, Noessner E, Lindner LH, et al. Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia. Eur J Cancer. 2021;158:123–132. doi: 10.1016/j.ejca.2021.09.015.
   PubMed Web of Science ®Google Scholar